American Society for Microbiology, Infection and Immunity, 9(87), 2019
DOI: 10.1128/iai.00276-19
Full text: Download
Multidrug-resistant enterococci are major causes of hospital-acquired infections. Immunotherapy with monoclonal antibodies (MAbs) targeting bacterial antigens would be a valuable treatment option in this setting. Here, we describe the development of two MAbs through hybridoma technology that target antigens from the most clinically relevant enterococcal species.